Skip to content
WorldBrand.AI
HomeAboutBrand WikiAEOWorld ModelComing SoonBlog
WorldBrand.AI

The intelligence platform for brands in the AI era.

Products
  • AEO Intelligence
  • Brand Wiki
  • World Model
  • Enterprise
Company
  • About
  • Blog
  • Pricing
Brand Wiki
  • About Brand Wiki
  • Methodology
  • Sources
  • Editorial policy
  • API

© 2026 WorldBrand.ai. All rights reserved.

Privacy PolicyTerms of Use

Sinopharm Group/Controversies

Sinopharm Group controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile

  1. 2017Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products
  2. Ineffective DPT vaccine incident (2017)

  1. 2017

    Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products

    Chinese regulatory sampling found that a DPT vaccine batch produced by Sinopharm’s Wuhan Institute of Biological Products failed potency requirements. Regulators reported that 400,520 doses were affected. The stated cause was a temporary filling-equipment malfunction that made the vaccine suspension uneven. Unused doses were recalled and destroyed, and the subsidiary was fined and required to strengthen equipment maintenance, filling procedures, training and quality controls.

    Source

  2. Ineffective DPT vaccine incident (2017)

    Source